Early Phase

When There’s A Lot At Stake,
We Put You On The Path To Success

Cmed is the CRO early phase clinical trials partner of choice for many pharmaceutical and biotechnology companies around the globe. With our first-hand knowledge and expertise applied, we focus on safety while placing careful attention on each dose and patient need.

Understanding that flexibility and speed are also vital to these stages of clinical development, our resident early phase oncology and rare disease experts can build both detail and flexibility into program and project planning to maximize success, all while mitigating potential issues with dosing protocols and adverse events..

An expert early phase team*
  • Clinical Operations
  • Clinical Data Management
  • Biostatisticians
  • Drug Safety
  • On-Staff Physicians
  • Project Management
  • Quality
  • Technology

*All with 100% oncology experience

Significant experience and solutions to ensure your Phase I & II trial goals are met

  • FIH and early phase protocol design, compliance, and delivery
  • Adaptive, Basket, Umbrella, All Comers, Traditional (e.g.,3+3), Innovative (e.g., accelerated titration), Bayesian, etc.
  • Investigational product changes/issues
  • Data and statistical considerations, challenges​, and review
  • Safety monitoring​
  • Enrollment and retention​ guidance, along with strategies for site engagement
  • Rare patient populations
  • Established site relationships
  • Regulatory submission and approvals

Project timelines can be reduced by weeks or months by our experts through protocol adjustments, intelligent use of decentralized services, and real time data visibility via our powerful, holistic technology platform, encapsia.

  • Instant access to all trial data, no matter the source
  • Insights that are actionable instantly via live data
  • Full compatibility with any mix of EDC, eSource, and third- party data sources

First In Human Clinical Trials

First In Human (FIH) oncology trials shouldn’t be entrusted to just any CRO. It’s imperative to partner with one who has first-hand knowledge and expertise in this critical first step where a focus on safety is paramount and each dose and patient is given careful attention. Understanding that flexibility and speed are also vital to this first stage of clinical development, our resident early phase oncology and rare disease experts can build both detail and flexibility into program and project planning to maximize success, all while mitigating potential issues with dosing protocols and adverse events.

Why work with us?

Helping you succeed in your project

100+

FIH studies

260+

Oncology studies

100%

Oncology experienced project teams

20+

Years as a full-service CRO in US & EU

Supporting Resources

Resources

Get in touch

Let’s support you on your next project